Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose.
Norio KomatsuYoshinori HashimotoTerumi BabaManami OtsukaTakafumi AkimotoJovelle FernandezPublished in: International journal of hematology (2022)
This surveillance showed that anagrelide has a tolerable safety and efficacy profile.